ceftriaxone
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
9900
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
December 05, 2025
Atypical HUS: Diagnostic challenge and therapeutic success with eculizumab
(ASH 2025)
- "She was treated with intravenous fluids and started on antibiotics with ceftriaxone and metronidazole for diverticulitis. Differentiating aHUS from TTP and STM-HUS is critical, as management strategies differ significantly. Prompt initiation of eculizumab can reverse renal injury and prevent further organ damage."
Acute Kidney Injury • Atypical Hemolytic Uremic Syndrome • Cardiovascular • Complement-mediated Rare Disorders • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Nephrology • Renal Disease • Thrombocytopenia • Thrombocytopenic Purpura • HP
December 05, 2025
Secondary HLH: A complication of anaplasmosis infection
(ASH 2025)
- "She was started on oral doxycycline 100 mg but due to worsening symptoms, ceftriaxone 2 grams twice daily was added due to concerns for neuroboreliosis. Secondary HLH is uncommon and can be due to varying causes including infection, malignancy, or immunodeficiency. Whereas, secondary HLH in the setting of anaplasmosis infection is an even more rare entity. It is imperative that infectious causes of secondary HLH be considered in the differential diagnosis because it signifies a very treatable cause of the HLH and promising outlook for the patient if treated appropriately."
Cardiovascular • Gastroenterology • Hemophagocytic lymphohistiocytosis • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Rare Diseases • CD8 • HP • IL2
November 04, 2025
Revisiting acute chest syndrome (ACS) associated with sickle cell disease (SCD) vaso-occlusive pain episodes (VOE): Insight from a prospective, multicenter Phase-3 randomized controlled trial
(ASH 2025)
- P3 | "ACSseverity was defined a priori as mild (no oxygen (O2) use or RBC transfusion), moderate (O2 use ortransfusion), or severe (bilevel positive airway pressure (BiPAP) use, intubation, or pediatric intensive careunit (PICU) transfer). 271 patients enrolled (median age 15[11,18] years, 51% male; 74% HbSS/Sb°; 76% onHydroxyurea (HU)...Across all sites, 96% of patients receivedantibiotics (50% ceftriaxone, 28% ampicillin-sulbactam, 7% vancomycin, 11% other) and 82% receivedazithromycin. Site-level use ranged from 0-100% for ceftriaxone and 50-100% for azithromycin... ACS remains common in patients with SCD-VOE (20%), with 14% of ACS diagnosed duringtheir hospital stay. Two-thirds of subjects who developed ACS had a CXR done in the ED that wasnegative. ACS may have been missed in patients who did not get a CXR, and radiographic changes oftenlag behind symptoms."
Clinical • P3 data • Addiction (Opioid and Alcohol) • Cardiovascular • Cough • Genetic Disorders • Hematological Disorders • Pain • Respiratory Diseases • Sickle Cell Disease
November 04, 2025
Reduced post-transplant alpha-diversity and domination by enterococcus faecium are associated with increased mortality in pediatric recipients of allogeneic hematopoietic cell transplantation.
(ASH 2025)
- "Prophylactic antibiotics variedby site: Rome utilized piperacillin/tazobactam (pip/tazo); MSK initially used ceftriaxone but transitionedto levofloxacin in 2020; and BCH used none.During the peri-transplant period (day -30 to day +30), microbiome α-diversity, as measured bySimpson reciprocal index, declined significantly post-HCT (median 4.0 pre- vs. 2.1 post-HCT; p<0.001)indicating substantial microbiome injury. This large, multicenter study highlights significant age- and center-specific variability in gut microbiomediversity and composition during pediatric allo-HCT. We found that reduced post-HCT a-diversity anddomination by Enterococcus faecium were associated with increased mortality."
Clinical • Post-transplantation • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Pediatrics • Transplantation
December 12, 2025
CPC03 Unusual cases of scalp ulceration: two distinct diagnoses.
(PubMed, Br J Dermatol)
- "She was treated with injectable steroids and cyclophosphamide, leading to peripheral healing of the lesions and significant improvement...The patient was treated initially with injectable ceftriaxone for 3 weeks, followed by oral penicillin G due to the unavailability of penicillin injections...Treatment modalities differ significantly, with GP requiring immunosuppressive therapy, and actinomycosis responding to prolonged antibiotic treatment. These cases highlight the diverse differential diagnoses of scalp ulceration and the need for a multidisciplinary approach to accurately identify and manage these rare conditions."
Journal • Immunology • Infectious Disease • Mood Disorders • Oncology • Otorhinolaryngology • Rare Diseases • Respiratory Diseases • Rheumatology • Vasculitis
December 12, 2025
β-Lactam dosing in critically ill children: predictors for target non-attainment.
(PubMed, J Antimicrob Chemother)
- "This study found an eGFR ≥90 mL/min/1.73 m2 to be associated with target non-attainment, indicating that kidney function should be taken into account when identifying individuals who may require higher dosages. These results may help identify subpopulations of paediatric patients requiring higher dosages or continuous infusion in order to achieve adequate β-lactam exposure."
Journal • Pediatrics
December 12, 2025
TAVeM2: Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis
(clinicaltrials.gov)
- P4 | N=103 | Terminated | Sponsor: University Hospital, Lille | N=154 ➔ 103 | Recruiting ➔ Terminated; lack of inclusion pandemic, investigator reluctance, lower than expected incidence of infection
Enrollment change • Trial termination • Respiratory Diseases
December 12, 2025
Enhanced Molecular Surveillance for Gonococcal Resistance During Doxycycline Post-Exposure Prophylaxis Implementation.
(PubMed, Int J Antimicrob Agents)
- "The introduction of doxycycline post-exposure prophylaxis (doxy-PEP) as a strategy to reduce the risk of bacterial sexually transmitted infections has raised concerns about the potential for rapid selection of tetracycline resistance and the emergence of ceftriaxone-resistant strains. Clinical sample testing revealed 100% sensitivity and specificity for identifying NG infection, tracking ceftriaxone-resistant FC428-like strains, and detecting tetM associated with tetracycline resistance. The HRM-doxyPEP assay offers an accurate, affordable, and scalable tool for enhanced molecular surveillance of AMR in NG during doxy-PEP implementation."
Journal • Infectious Disease
December 11, 2025
Effectiveness of antibiotic prophylaxis for ventilator-associated pneumonia in acute brain injury: a systematic review and meta-analysis.
(PubMed, Infection)
- "Short-course AP reduces early/overall VAP and LOS in ABI without impacting late VAP or mortality, supporting targeted use in high-risk cases (e.g., GCS < 8) per stewardship principles. However, heterogeneity, resistance gaps, and guideline caution warrant larger RCTs with non-ABI comparatives to mitigate selection bias and confirm specificity."
Journal • Retrospective data • Cardiovascular • CNS Disorders • Infectious Disease • Pneumonia • Respiratory Diseases • Vascular Neurology
December 11, 2025
Fever of Unknown Origin and Penetrating Aortic Ulcer Successfully Treated with Thoracic Endovascular Aortic Repair-A Case Report.
(PubMed, Diagnostics (Basel))
- "With administration of both ceftriaxone and levofloxacin, a decrease in CRP was monitored (51 mg/L). As sophisticated imaging techniques become more widely used, more PAUs are being detected as incidental abnormalities in individuals without acute aortic syndrome. With adequate management, many people with PAU can live a stable and healthy life without experiencing significant consequences."
Journal • Atherosclerosis • Cardiovascular • Hematological Disorders • Infectious Disease • Oncology • Thrombocytosis • Vasculitis
December 11, 2025
Pediatric Complicated Appendicitis: Results of a Standardized Antibiotic Protocol in a Tertiary Center.
(PubMed, J Pediatr Surg)
- "One in seven children with CA required an antibiotic switch. Elevated preoperative CRP levels and intra-abdominal abscess were significantly associated with the need for CM to PT switch. These patients may benefit from first-line PT treatment."
Journal • Gastroenterology • Gastrointestinal Disorder • Pediatrics • CRP
December 10, 2025
99mTc-labeled antibiotics for infection imaging along with diagnostic potential: a comparative study of cephalosporin and fluoroquinolone.
(PubMed, Nucl Med Commun)
- "This study examines 99mTc labeling of cefixime, ceftriaxone, and ciprofloxacin, achieving high binding efficiency. It compares their potential in infection imaging, distinguishing infections from inflammation, and exploring therapeutic applications."
Clinical • Journal • Infectious Disease • Inflammation
December 10, 2025
From Commensal to Pathogen: Unveiling Klebsiella pneumoniae subsp. ozaenae as a Cause of Meningitis and a Literature Review.
(PubMed, Cureus)
- "In spite of the treatment received with ceftriaxone and vancomycin, he unfortunately succumbed to the disease. After a thorough literature review, this is the first fatal documented case of Klebsiella ozaenae meningitis in a young male in India that proves the rarity of this infection as well as the virulence of the organism."
Journal • Cardiovascular • CNS Disorders • Diabetes • Hypertension • Infectious Disease • Inflammation • Metabolic Disorders • Pneumonia
December 09, 2025
Robot-Assisted Stereotactic Aspiration of a Parietal Brain Abscess With Metagenomic Identification of Fusobacterium nucleatum.
(PubMed, J Craniofac Surg)
- "Metagenomic next-generation sequencing identified F. nucleatum, prompting adjustment of antibiotics to ceftriaxone plus metronidazole, followed by metronidazole monotherapy. The patient improved clinically, and a 6-month MRI confirmed complete resolution, underscoring the precision of robotic stereotaxy for eloquent-region abscesses and highlighting the diagnostic value of metagenomic sequencing in detecting anaerobic pathogens."
Journal • CNS Disorders
December 09, 2025
An Atypical Presentation of Enteroviral Meningitis in an Immunocompetent Adult Man.
(PubMed, Cureus)
- "The patient was started empirically on intravenous (IV) ceftriaxone, vancomycin, and acyclovir. This case underscores that early LP and comprehensive diagnostic evaluation are essential when clinical findings are nonspecific. Maintaining a broad differential and relying on clinical judgment rather than physical signs alone can help prevent missed or delayed diagnoses."
Journal • Cardiovascular • CNS Disorders • Hypertension • Infectious Disease • Inflammation • Musculoskeletal Pain • Pain
December 09, 2025
Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE.
(PubMed, BMJ Open)
- P=N/A | "The vanguard phase demonstrated overall trial feasibility by recruitment rate and protocol adherence, with differences across interventions, leading to a transition to the main BALANCE+ platform trial with minimal protocol modifications."
Clinical • Journal • Critical care • Infectious Disease
December 08, 2025
Novel drug-loaded nano-polymer comparison: amoxicillin between ceftriaxone for MCF-7 breast cancer cytotoxicity.
(PubMed, J Biomater Sci Polym Ed)
- "This work establishes a scalable nano-polymer platform for antibiotic repurpose, identifies ceftriaxone as a superior candidate for breast cancer therapy, and provides a critical mechanistic bridge between drug chemistry and tumor biology. With its established clinical safety, this ceftriaxone-based system represents a viable candidate for rapid translation to in vivo studies."
Journal • Breast Cancer • Oncology • Solid Tumor
December 08, 2025
Community-acquired pneumonia-causing bacteria and antibiotic resistance rate among Syrian patients.
(PubMed, J Infect Dev Ctries)
- "These findings underscore the importance of being able to adapt the general World Health Organization recommendations according to local evidence. It is crucial to emphasize the need for continuous local monitoring, functioning and well-equipped laboratories, and well-trained specialists in infectious diseases in hospitals to be able to make these decisions."
Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases
December 07, 2025
Antibiotic-Associated Encephalopathy Induced by Cefmetazole in a Hemodialysis Patient: Case Report.
(PubMed, J Infect Chemother)
- "While cefepime, ceftazidime, and ceftriaxone are well-documented causes, cefmetazole (CMZ) has not been widely recognized for neurotoxicity. A Naranjo score of 5 supported a diagnosis of CMZ-induced AAE. This case underscores the potential neurotoxicity of CMZ and emphasizes the importance of early recognition of AAE in patients with renal dysfunction."
Journal • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Epilepsy • Infectious Disease • Movement Disorders • Nephrology • Renal Disease
December 07, 2025
Implementing Pediatric Appendicitis Pathways Across Multiple Hospitals: A Quality Improvement Project.
(PubMed, J Pediatr Surg)
- "An appendicitis pathway can successfully be scaled and implemented across a children's hospital system, decreasing LOS and narcotic prescriptions at discharge without increasing returns to the system."
Journal • Gastroenterology • Gastrointestinal Disorder • Pain • Pediatrics
December 06, 2025
Infection risks and biopsy-associated complications in prostate cancer diagnosis: a review of recent literatures.
(PubMed, Prostate Cancer Prostatic Dis)
- "Modern evidence supports a paradigm shift toward TP-Bx combined with targeted or multidrug prophylaxis to mitigate infectious risks. Imaging-guided and robotic-assisted techniques enhance diagnostic accuracy and safety but remain limited in resource-constrained settings. TRUS-Bx retains utility where TP access is unavailable; however, adapting infection prevention strategies is critical. Future large-scale trials and cost-effectiveness analyses are needed to optimize biopsy protocols globally."
Journal • Review • Anesthesia • Genito-urinary Cancer • Infectious Disease • Nephrology • Oncology • Prostate Cancer • Septic Shock • Solid Tumor
December 05, 2025
Evaluation of antibiotic consumption in Intensive Care Units of a teaching hospital based on defined daily dose metrics and WHO Access, Watch, Reserve classification framework.
(PubMed, J Postgrad Med)
- "The study demonstrates excessive use of 'Watch' antibiotics and a relative underuse of 'Access' agents in ICUs, emphasizing the scope for implementing robust stewardship measures including culture-guided de-escalation, formulary restriction of broad-spectrum agents, and implementing stringent surgical prophylaxis protocols."
Journal • Critical care
December 05, 2025
Repurposing epetraborole to combat Neisseria gonorrhoeae and Chlamydia trachomatis infections.
(PubMed, Antimicrob Agents Chemother)
- "Ceftriaxone (CRO) is the only recommended treatment for gonococcal infections but has no activity against C. trachomatis. Azithromycin (AZM) or doxycycline (DOX) is recommended for C. trachomatis infections; however, N. gonorrhoeae has developed resistance to both agents...Finally, in an in vivo mouse model of CRO-resistant N. gonorrhoeae genital tract infection, EBO exhibited a 99.95% reduction in bacterial burden after 2 days of treatment. Collectively, our findings highlight EBO as a promising candidate for the treatment of sexually transmitted infections that warrants further investigation."
Journal • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases
December 05, 2025
Pathogen distribution, antimicrobial resistance and attributable cost analysis of neonatal sepsis in neonatal intensive care units: a propensity score matching study.
(PubMed, Front Pediatr)
- "Antimicrobial resistance analysis revealed high resistance rates of Gram-positive bacteria to penicillin G (94.6%) and oxacillin (89.3%). Gram-negative pathogens exhibited high resistance to levofloxacin (75.0%), ceftriaxone (66.7%), cefepime (66.7%), and meropenem (58.3%)...NS significantly increases the hospitalization resource consumption in NICUs. This study provides key evidence for optimizing antibiotic use strategies and advancing precision healthcare payment reform, and calls for integrating resistance surveillance with cost-control measures to reduce the health economic impact of NS."
HEOR • Journal • Critical care • Infectious Disease • Septic Shock
December 05, 2025
Sandwiched ceftriaxone-impregnated oxidized regenerated cellulose within electrospun gelatin/polylactic acid fibers for enhanced wound management.
(PubMed, Int J Biol Macromol)
- "Overall, the ceftriaxone-embedded Gel/PLA nanofibrous composite demonstrated high biocompatibility (>90 %) and multifunctional performance. By integrating effective hemostasis, sustained antibacterial delivery, and structural support for tissue regeneration, this advanced wound dressing offers a promising approach for accelerating wound healing and preventing infection in biomedical applications."
Journal • Infectious Disease
1 to 25
Of
9900
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396